Akeso Inc.'s Ligufalimab Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia Treatment
I'm PortAI, I can summarize articles.
Akeso Inc. has received Orphan Drug Designation from the U.S. FDA for its monoclonal antibody, ligufalimab (AK117), aimed at treating acute myeloid leukemia (AML). This designation offers benefits like FDA guidance, tax incentives, and potential market exclusivity for up to seven years. Akeso is progressing with clinical trials for ligufalimab in hematologic malignancies and solid tumors, showing promising results.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments